Scholarlink

Study Objectives: <p>The incidence of sleep-related breathing disorder remains unclear in patients with a continuous flow left ventricular assist device. Polysomnography (PSG) remains the gold standard for diagnosis, but logistical challenges make home sleep apnea testing a more practical alternative. WatchPat has failed to accurately diagnose sleep-related breathing disorder in this population. In contrast, the NOX-T3 utilizes more channels to monitor physiological variables, potentially offering improved diagnostic accuracy. Therefore, we aimed to validate the NOX-T3 vs PSG in detecting sleep-related breathing disorder in patients with a durable left ventricular assist device.</p> Methods: <p>This is a single-center, prospective, observational pilot study. Patients with left ventricular assist device who screened positive on the STOP-BANG Sleep Apnea Questionnaire were referred to sleep clinic. Patients recommended for PSG by a sleep physician underwent PSG and NOX-T3 simultaneously. Apnea-hypopnea index with the PSG and the respiratory event index using the NOX-T3 were compared as well as time spent with oxygen saturation ≤ 88% using Spearman’s correlation. <i>P</i> values less than .05 were considered statistically significant.</p> Results: <p>Ten patients (8 males, 2 females) were enrolled. The average age was 54 ± 15 years and 9 were implanted with a HeartMate III device. There was a strong correlation between the apnea-hypopnea index obtained from NOX-T3 and PSG (<i>R</i><sup>2</sup> = .984) but the time spent with oxygen saturation ≤ 88% correlated poorly (<i>r</i> = .168). The tests identified the same 3 patients meeting the diagnostic criteria for obstructive sleep apnea.</p> Conclusions: <p>Our results suggest that the NOX-T3 home sleep apnea testing device is a useful tool in the comprehensive evaluation of sleep-related breathing disorder in patients with left ventricular assist device.</p> Citation: <p>Mutirangura P, Alexy T, Airhart SE, et&#xa0;al. Home sleep apnea testing in patients with continuous flow left ventricular assist device: is it feasible? <i>J Clin Sleep Med</i>. 2025;21(6):999–1005.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Home sleep apnea testing in patients with continuous flow left ventricular assist device: is it feasible?

  • 期刊论文

  • 发表日期：

    2025年6月1日

查看全文
  • Pornthira Mutirangura,
  • Tamas Alexy,
  • Sophia E. Airhart,
  • Jenna E. Kay,
  • Antonio C. Christophy,
  • Dominic Emerson,
  • David Raymer,
  • Andrew W. Shaffer,
  • Anthony W. Castleberry,
  • Marshall P. Hyden,
  • Karol Mudy,
  • Benjamin Sun,
  • Snigdha Pusalavidyasagar

摘要

Study Objectives:

The incidence of sleep-related breathing disorder remains unclear in patients with a continuous flow left ventricular assist device. Polysomnography (PSG) remains the gold standard for diagnosis, but logistical challenges make home sleep apnea testing a more practical alternative. WatchPat has failed to accurately diagnose sleep-related breathing disorder in this population. In contrast, the NOX-T3 utilizes more channels to monitor physiological variables, potentially offering improved diagnostic accuracy. Therefore, we aimed to validate the NOX-T3 vs PSG in detecting sleep-related breathing disorder in patients with a durable left ventricular assist device.

Methods:

This is a single-center, prospective, observational pilot study. Patients with left ventricular assist device who screened positive on the STOP-BANG Sleep Apnea Questionnaire were referred to sleep clinic. Patients recommended for PSG by a sleep physician underwent PSG and NOX-T3 simultaneously. Apnea-hypopnea index with the PSG and the respiratory event index using the NOX-T3 were compared as well as time spent with oxygen saturation ≤ 88% using Spearman’s correlation. P values less than .05 were considered statistically significant.

Results:

Ten patients (8 males, 2 females) were enrolled. The average age was 54 ± 15 years and 9 were implanted with a HeartMate III device. There was a strong correlation between the apnea-hypopnea index obtained from NOX-T3 and PSG (R2 = .984) but the time spent with oxygen saturation ≤ 88% correlated poorly (r = .168). The tests identified the same 3 patients meeting the diagnostic criteria for obstructive sleep apnea.

Conclusions:

Our results suggest that the NOX-T3 home sleep apnea testing device is a useful tool in the comprehensive evaluation of sleep-related breathing disorder in patients with left ventricular assist device.

Citation:

Mutirangura P, Alexy T, Airhart SE, et al. Home sleep apnea testing in patients with continuous flow left ventricular assist device: is it feasible? J Clin Sleep Med. 2025;21(6):999–1005.